ProCE Banner Activity

COVID-19 in Immunocompromise: What I Do and Why

Clinical Thought

When considering treatment for people with COVID-19 who are immunocompromised, several gaps exist because current recommendations are based on studies that often excluded this group of patients. Here is why I think antivirals should be considered regardless of disease severity.

Released: January 22, 2025

Expiration: January 21, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

American Academy of Emergency Medicine (AAEM)

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

ProCE

ProCE Banner

Faculty Disclosure

Primary Author

Michele Bartoletti, MD, PhD

Associate Professor of Infectious Diseases
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele (MI), Italy
Head of Infectious Diseases Unit
IRCCS Humanitas Research Hospital
Rozzano (MI), Italy

Michele Bartoletti, MD, PhD, has no relevant financial relationships to disclose.